HemaSphere
(Aug 2023)
PB2306: REAL-WORLD FIRST-LINE TREATMENT AND OUTCOMES AMONG PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE
- Jiali Yan,
- Shilpa Shahani,
- Nancy Smith,
- Fang Sun,
- Qinghua Song,
- Hairong Xu,
- Jie Zhang,
- Umar Farooq
Affiliations
- Jiali Yan
- 1 Kite, a Gilead Company, Santa Monica, United States
- Shilpa Shahani
- 1 Kite, a Gilead Company, Santa Monica, United States
- Nancy Smith
- 1 Kite, a Gilead Company, Santa Monica, United States
- Fang Sun
- 1 Kite, a Gilead Company, Santa Monica, United States
- Qinghua Song
- 1 Kite, a Gilead Company, Santa Monica, United States
- Hairong Xu
- 1 Kite, a Gilead Company, Santa Monica, United States
- Jie Zhang
- 1 Kite, a Gilead Company, Santa Monica, United States
- Umar Farooq
- 2 University of Iowa, Iowa City, United States
- DOI
-
https://doi.org/10.1097/01.HS9.0000975948.06586.80
- Journal volume & issue
-
Vol. 7
p.
e0658680
WeChat QR code